3 Branded Drug Maker, Fluorine Chemicals Maker and Transformers Maker Stocks With a Strong Future Roadmap: JB Chemicals and Pharmaceuticals, Navin Fluorine International and CG Power and Industrial Solutions

Branded drug, fluorine and electrical stocks let investors follow companies that serve a growing part of the Indian economy. JB Chemicals and Pharmaceuticals, Navin Fluorine International and CG Power and Industrial Solutions cover a branded formulations maker, a specialty fluorine chemicals maker and a transformers and motors maker.

This list covers three branded drug, fluorine and electrical stocks with complete current figures: JB Chemicals and Pharmaceuticals, Navin Fluorine International and CG Power and Industrial Solutions. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Branded Drug, Fluorine and Electrical Stocks?

Branded drug, fluorine and electrical stocks are listed companies that sell branded formulations in cardiac, gastro-intestinal and other care, make refrigerant gases and specialty fluorochemicals, and produce transformers, motors, switchgear and railway equipment. Their earnings depend on prescriptions, global chemical orders and grid and rail investment.

Branded Drug, Fluorine and Electrical Stocks at a Glance

On valuation, all three trade at a P/E above their industry P/E, which reflects the growth the market already expects from them. Readers comparing branded drug, fluorine and electrical stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in branded drug, fluorine and electrical stocks can use the coming numbers to test whether growth is holding.

Why Do Branded Drug, Fluorine and Electrical Stocks Have a Strong Roadmap in India?

Branded drug, fluorine and electrical stocks have a strong roadmap in India because growing medicine use, wider specialty chemical applications and large grid and rail investment keep widening the market for these companies.

• Branded drugs. Chronic care medicines see steady use.
• Fluorine chemicals. Cooling and pharma users need specialty inputs.
• Electrical equipment. Utilities and railways need transformers and motors.

Why JB Chemicals and Pharmaceuticals Features Among These Branded Drug, Fluorine and Electrical Stocks

Among the branded drug, fluorine and electrical stocks on this list, JB Chemicals and Pharmaceuticals is a Mumbai-based pharmaceutical company that sells branded formulations in India in cardiac, gastro-intestinal and other therapies, exports to several markets and runs a contract development and manufacturing business.

Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%.

The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8.

Roadmap: The company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.

What to watch: Monitor the growth of key domestic brands and the order flow in contract manufacturing.

Why Navin Fluorine International Features Among These Branded Drug, Fluorine and Electrical Stocks

Among the pharma, chemistry and power equipment shares on this list, Navin Fluorine International is a specialty fluorine chemicals company that makes refrigerant gases, specialty fluorochemicals, and custom research and manufacturing services for pharma and agrochemical clients.

In the June 2026 quarter, revenue grew 46.1% year on year to Rs 1,080 crore, while net profit rose 107.7% to Rs 243 crore. Revenue rose from Rs 1,493 crore in FY22 to Rs 3,379 crore in FY26, a compound annual growth rate of 22.7%.

Net profit grew from Rs 263 crore in FY22 to Rs 664 crore in FY26, which works out to a compound annual growth rate of 26.0%. The company has a return on equity of 16.7%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 41,847 crore. The stock trades at a P/E of 53.0, above the industry P/E of 35.1.

Roadmap: Growth is driven by specialty chemicals, contract manufacturing for global partners and new fluorination capacity. The company has also added capacity for products linked to battery and clean energy applications.

What to watch: Check the ramp-up of new capacity and the share of the contract manufacturing business in revenue.

Why CG Power and Industrial Solutions Features Among These Branded Drug, Fluorine and Electrical Stocks

Among the three companies on this list, CG Power and Industrial Solutions makes transformers, motors, switchgear, drives and railway equipment for utilities, industry and railways, and has also entered semiconductor packaging.

The company has a return on equity of 15.1%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 134,561 crore. The stock trades at a P/E of 108.5, above the industry P/E of 43.9.

Revenue rose from Rs 5,521 crore in FY22 to Rs 12,662 crore in FY26, a compound annual growth rate of 23.1%. Net profit grew from Rs 630 crore in FY22 to Rs 1,197 crore in FY26, which works out to a compound annual growth rate of 17.4%. In the June 2026 quarter, revenue grew 15.8% year on year to Rs 3,364 crore, while net profit rose 15.5% to Rs 308 crore.

Roadmap: The company is growing in power systems and industrial systems on the back of grid expansion and factory investment. It has built an outsourced semiconductor assembly and test plant, which opens a new technology line.

What to watch: Monitor the ramp-up of its semiconductor facility and order intake in power systems.

JB Chemicals and Pharmaceuticals vs Navin Fluorine International vs CG Power and Industrial Solutions on Key Financials

The table below sets the three branded drug, fluorine and electrical stocks side by side on revenue, profit and margin, using reported figures.

JB Chemicals and Pharmaceuticals posts the highest return on equity in this group at 17.1%. CG Power and Industrial Solutions combines the largest FY26 revenue at Rs 12,662 crore with the fastest revenue growth, a 23.1% compound annual rate. A useful habit with branded drug, fluorine and electrical stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several formulation, refrigerant gas and transformer stocks instead of one name, which keeps a single result from deciding the outcome.

Key Risks to Check Before Investing in Branded Drug, Fluorine and Electrical Stocks

Every theme carries risks that deserve a check before any decision. For these branded drug, fluorine and electrical stocks, the main points are: Long-term pharma, chemistry and power equipment shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Order timing. Project awards can shift between periods.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter branded drug, fluorine and electrical stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Branded Drug, Fluorine and Electrical Stocks

Branded drug, fluorine and electrical stocks reward investors who follow demand trends, order books and margins together. JB Chemicals and Pharmaceuticals, Navin Fluorine International and CG Power and Industrial Solutions each have a clear plan to grow. Based on the 4 November 2026 close, JB Chemicals and Pharmaceuticals trades at Rs 2,408.9, Navin Fluorine International at Rs 8,777 and CG Power and Industrial Solutions at Rs 841.45. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these branded drug, fluorine and electrical stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track branded drug, fluorine and electrical stocks, set price alerts and get research-backed stock ideas.

What are branded drug, fluorine and electrical stocks?

Ans. Branded drug, fluorine and electrical stocks are listed companies that sell branded formulations in cardiac, gastro-intestinal and other care, make refrigerant gases and specialty fluorochemicals, and produce transformers, motors, switchgear and railway equipment. Their earnings depend on prescriptions, global chemical orders and grid and rail investment. This list looks at three of them, JB Chemicals and Pharmaceuticals, Navin Fluorine International and CG Power and Industrial Solutions, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.

Which branded drug, fluorine and electrical stocks are covered in this list?

Ans. This list covers JB Chemicals and Pharmaceuticals, Navin Fluorine International and CG Power and Industrial Solutions. Based on the 4 November 2026 close, JB Chemicals and Pharmaceuticals traded at Rs 2,408.9, Navin Fluorine International at Rs 8,777 and CG Power and Industrial Solutions at Rs 841.45. Their return on equity ranges from 15.1% to 17.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 14.3% to 23.1%.

Why do branded drug, fluorine and electrical stocks have a strong future roadmap in India?

Ans. Branded drug, fluorine and electrical stocks have a strong roadmap in India because growing medicine use, wider specialty chemical applications and large grid and rail investment keep widening the market for these companies. The main drivers are as follows. Branded drugs. Chronic care medicines see steady use. Fluorine chemicals. Cooling and pharma users need specialty inputs. Electrical equipment. Utilities and railways need transformers and motors. Together these factors give the companies on this list a visible path for growth over the coming years.

How has JB Chemicals and Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%. The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8. Looking ahead, the company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.

How has Navin Fluorine International performed financially?

Ans. Revenue rose from Rs 1,493 crore in FY22 to Rs 3,379 crore in FY26, a compound annual growth rate of 22.7%. Net profit grew from Rs 263 crore in FY22 to Rs 664 crore in FY26, which works out to a compound annual growth rate of 26.0%. In the June 2026 quarter, revenue grew 46.1% year on year to Rs 1,080 crore, while net profit rose 107.7% to Rs 243 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 41,847 crore. The stock trades at a P/E of 53.0, above the industry P/E of 35.1. Looking ahead, growth is driven by specialty chemicals, contract manufacturing for global partners and new fluorination capacity. The company has also added capacity for products linked to battery and clean energy applications.

How has CG Power and Industrial Solutions performed financially?

Ans. Revenue rose from Rs 5,521 crore in FY22 to Rs 12,662 crore in FY26, a compound annual growth rate of 23.1%. Net profit grew from Rs 630 crore in FY22 to Rs 1,197 crore in FY26, which works out to a compound annual growth rate of 17.4%. In the June 2026 quarter, revenue grew 15.8% year on year to Rs 3,364 crore, while net profit rose 15.5% to Rs 308 crore. The company has a return on equity of 15.1%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 134,561 crore. The stock trades at a P/E of 108.5, above the industry P/E of 43.9. Looking ahead, the company is growing in power systems and industrial systems on the back of grid expansion and factory investment. It has built an outsourced semiconductor assembly and test plant, which opens a new technology line.

What risks should investors check before buying branded drug, fluorine and electrical stocks?

Ans. Investors should check a few risks before buying branded drug, fluorine and electrical stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Order timing. Project awards can shift between periods. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of branded drug, fluorine and electrical stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.